---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-015988"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T16:46:54.018202+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience Q2 revenue record $60.2M (+25% YoY); cuts 270 jobs (~25% workforce)

## Summary
- Revenue $60.2M, up 25% YoY; orders $64.2M, up 17% YoY.
- Net loss $59.2M ($1.04 EPS) vs $60.7M ($1.13) prior year.
- Workforce reduction of ~270 employees (~25%); expects pre-tax charges $9-11M.
- Withdrew prior FY2024 guidance; provided limited updated guidance focused on cost reduction.
- Cash $387.7M; shipped to 2,100 customers, 152k genes.

## SEC filing metadata
- accession: 0001628280-23-015988
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000162828023015988/0001628280-23-015988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000162828023015988/twist-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-015988
- JSON: https://secwatch.observer/filing/0001628280-23-015988.json
- Plain text: https://secwatch.observer/filing/0001628280-23-015988.txt

## Key facts
- Earnings Releases
  Twist Bioscience Corp reported fiscal second quarter ended March 31, 2023 results: revenue Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of, net income Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share, EPS $1.04 per share.
  - Period: fiscal second quarter ended March 31, 2023
  - Revenue: Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of
  - Net income: Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share
  - EPS: $1.04 per share
  - Result: reported results
  source text: Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of fiscal 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828023015988/0001628280-23-015988-index.htm
- Earnings Releases
  Twist Bioscience Corp reported fiscal second quarter ended March 31, 2023 results: revenue Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of, net income Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share, EPS $1.04 per share.
  - Period: fiscal second quarter ended March 31, 2023
  - Revenue: Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of
  - Net income: Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share
  - EPS: $1.04 per share
  - Result: reported results
  source text: Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share, compared to $60.7 million, or $1.13 per share, for the same period of fiscal 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828023015988/0001628280-23-015988-index.htm
- Earnings Releases
  Twist Bioscience Corp reported fiscal 2023 results: revenue Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22.
  - Period: fiscal 2023
  - Revenue: Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22
  - Result: guidance update
  source text: expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results – Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22 – – Orders increased to $64.2M in 2QFY23; up 17% over 2QFY22 – -- Decisive Actions to Accelerate Path to Profitability -- SOUTH SAN
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828023015988/0001628280-23-015988-index.htm
- Restructurings & Charges
  Twist Bioscience Corp announced a restructuring with charges of between $9 and $11 million affecting worldwide (approximately 270 employees).
  - Type: restructuring
  - Charge: between $9 and $11 million
  - Affected area: worldwide
  - Headcount: approximately 270 employees
  source text: On May 3, 2023, the Company’s board of directors approved a strategic restructuring plan, which includes a reduction in force affecting approximately 270 employees worldwide, representing approximately 25% of the Company’s total workforce. The Company expects the plan to be implemented beginning in the third quarter of fiscal year 2023 and substantially completed by the end of fiscal year 2023. The Company expects to incur pre-tax charges of between $9 and $11 million, consisting of cash expenditures for employee severance and related benefit costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828023015988/0001628280-23-015988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.